The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non‐small cell lung cancer

Abstract

The IBI was independently associated with overall survival, 90-day outcomes, length of hospitalization, hospitalization expenses and cachexia in NSCLC patients. As an optimal systemic inflammation biomarker, the IBI has broad clinical application prospects in predicting the prognosis of patients with NSCLC.